- Home
- IFRX vs PBBK Comparison
IFRX vs PBBK Comparison
Compare IFRX & PBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- PBBK
- Stock Information
- Founded
- IFRX 2007
- PBBK 1919
- Country
- IFRX Germany
- PBBK United States
- Employees
- IFRX N/A
- PBBK N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- PBBK Banks
- Sector
- IFRX Health Care
- PBBK Finance
- Exchange
- IFRX Nasdaq
- PBBK Nasdaq
- Market Cap
- IFRX 56.4M
- PBBK 45.2M
- IPO Year
- IFRX 2017
- PBBK N/A
- Fundamental
- Price
- IFRX $0.79
- PBBK N/A
- Analyst Decision
- IFRX Strong Buy
- PBBK
- Analyst Count
- IFRX 4
- PBBK 0
- Target Price
- IFRX $7.75
- PBBK N/A
- AVG Volume (30 Days)
- IFRX 282.5K
- PBBK 7.3K
- Earning Date
- IFRX 08-07-2025
- PBBK 08-13-2025
- Dividend Yield
- IFRX N/A
- PBBK N/A
- EPS Growth
- IFRX N/A
- PBBK 12.16
- EPS
- IFRX N/A
- PBBK 0.83
- Revenue
- IFRX $140,242.00
- PBBK $12,804,000.00
- Revenue This Year
- IFRX N/A
- PBBK N/A
- Revenue Next Year
- IFRX $6,309.47
- PBBK N/A
- P/E Ratio
- IFRX N/A
- PBBK $20.84
- Revenue Growth
- IFRX 30.90
- PBBK 5.21
- 52 Week Low
- IFRX $0.71
- PBBK $14.05
- 52 Week High
- IFRX $2.82
- PBBK $19.05
- Technical
- Relative Strength Index (RSI)
- IFRX 37.43
- PBBK 53.08
- Support Level
- IFRX $0.78
- PBBK $17.30
- Resistance Level
- IFRX $0.83
- PBBK $18.50
- Average True Range (ATR)
- IFRX 0.04
- PBBK 0.71
- MACD
- IFRX 0.03
- PBBK -0.04
- Stochastic Oscillator
- IFRX 52.00
- PBBK 39.72
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About PBBK PB Bankshares Inc.
PB Bankshares Inc follows a community bank model and provides multiple services to individuals and small to midsize businesses. Its business consists of attracting retail and commercial deposits from the general public in its market area and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial and industrial loans, construction, home equity lines of credit and to a lesser extent, one- to four-family residential real estate loans and consumer loans.